Synergy Pharmaceuticals Inc (SGYP) - Financial Analysis Review

Summary

Synergy Pharmaceuticals Inc (Synergy Pharma), a subsidiary of Pawfect Foods Inc, develops therapies for gastrointestinal (GI) diseases using its proprietary GI platform, which is based on uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company concentrates in therapeutic areas such as chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and ulcerative colitis (UC). Synergy Pharmas product portfolio includes plecanatide (SP-304), a drug candidate, which is used to treat CIC and IBS-C; and dolcanatide (SP-333) for the treatment of OIC and UC.

GlobalData's Synergy Pharmaceuticals Inc (SGYP) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Synergy Pharmaceuticals Inc Key Recent Developments:

Nov 09,2016: Synergy Pharmaceuticals Reports Third Quarter 2016 Financial Results and Business Update
Aug 08,2016: Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results and Business Update
May 10,2016: Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update
Apr 28,2016: Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer
Mar 10,2016: Synergy Pharmaceuticals Appoints Marino Garcia as Chief Strategy Officer


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage